Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma (PIOPPO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03822936
Recruitment Status : Recruiting
First Posted : January 30, 2019
Last Update Posted : September 5, 2021
Sponsor:
Collaborator:
Foundation IRCCS San Matteo Hospital
Information provided by (Responsible Party):
Francesca Valvo, CNAO National Center of Oncological Hadrontherapy

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Relapses free survival will be evaluated as efficacy of carbon ions radiation therapy released before surgery.

Condition or disease Intervention/treatment Phase
Cancer of Pancreas Pancreas Adenocarcinoma Resectable Pancreatic Cancer Drug: Preoperative chemotherapy Radiation: Preoperative radiotherapy Phase 2

Detailed Description:

Enrolled subjects will undergo to 3 cycles of Folfirinox before re-evaluation of the lesion. Then, 4D planning and imaging with respiratory gating end rescanning technique will be adopted to calculate the optimal treatment plan to carbon ions radiation therapy: 38.4 Gy[RBE] is the prescribed dose to CTV. 4.8 Gy[RBE]/fraction will be delivered 4 times a week in two weeks. 4/6 weeks after hadrontherapy, after a CT scan with contrast, patient will undergo to a surgery. After 4/6 weeks, Gemcitabine will be administered for 6 cycles.

Secondary endpoints of the trial are overall survival, resectability rate (operable vs borderline operable), acute toxicity within 3 months, 3-6 months, over 6 months.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: The trial enrolls subjects that will receive in order: chemotherapy, carbon ion therapy, followed by surgical resection after 4/6 weeks then adjuvant chemotherapy.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Clinical Study on Resectable or Borderline Resectable Pancreas Adenocarcinoma Preoperative Treatment With Chemotherapy and Carbon Ions Radiation Therapy (Hadrontherapy)
Actual Study Start Date : February 8, 2018
Estimated Primary Completion Date : February 8, 2023
Estimated Study Completion Date : February 8, 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Preoperatory chemoradiation therapy with carbon ions
Chemoradiation followed by surgery
 Drug: Preoperative chemotherapy
Preoperative chemotherapy, carbon ion therapy, surgery
Other Name: Folinic acid, Irinotecan, fluorouracil, oxaliplatin

Radiation: Preoperative radiotherapy
Preoperative chemotherapy, carbon ion therapy, surgery
Other Name: Carbon ion therapy


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Progression free survival [ Time Frame: The local progression free survival will be assessed at 1-year ]
    The local progression free survival is measured


Secondary Outcome Measures :
  1. overall survival [ Time Frame: The overall survival of enrolled patients will be assessed at 2-years ]
    the overall survival of enrolled patients is considered

  2. resectability rate R0 stratified (operable vs not operable) [ Time Frame: time of surgery (4-6 weeks after radiotherapy) ]
    how many surgeries completed according to the procedures and with histopathological margins free from the disease/enrolled patients

  3. Incidence of acute, medium term and late toxicity according to CTCAE v 4.0 grading toxicity [ Time Frame: The incidence of acute and medium term toxicity will be assessed up to 90 and 180 post-operative days respectively. The incidence of late toxicity will be assessed through study completion, an average of 1 year. ]
    Incidence of acute, medium term and late toxicity according to CTCAE v 4.0 grading toxicity

  4. intra and perioperatory complications [ Time Frame: The incidence of intra- and perioperatory complications will be assessed up to 30 post-operative days ]
    intra and perioperatory complications


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • histologic/cytologic diagnosis of exocrine pancreas tumour
  • resectable or borderline resectable exocrine pancreatic tumour (according to operability criteria)
  • no metastasis from US, CT, PET, MRI or laparotomy
  • Karnofsky index >= 70
  • stomach and duodenum not infiltrated by tumour
  • given informed consent to study procedures
  • Hb > 9 g/dL, N> 1500, PLT> 100000
  • creatininemia < 1.5 mg/dL; bilirubinemia < 1.5 times upper normal values; albumin > 3 g/dL
  • DPD normal activity
  • contraception required and breast feeding not permitted

Exclusion Criteria:

  • non resectable, locally advanced tumours
  • insular cells tumour
  • comorbidities excluding abdominal surgery and/or chemo- radiation therapy
  • known metastasis
  • DPD low activity
  • inability to attend study procedures and follow ups
  • pregnancy
  • previous diagnosis of other tumour with more disadvantageous prognosis then the study object
  • metallic biliary stent
  • metallic prothesis or any other condition to prevent from target volume individuation and dose calculation
  • clinical condition preventing from radiation therapy (i.e. infections in the irradiation area)
  • medical and/or psychical condition preventing from radiation therapy
  • past radiation therapy on abdomen.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03822936


Contacts
Layout table for location contacts
Contact: Francesca Valvo, MD 0039(0)382078501 ext 612 francesca.valvo@cnao.it
Contact: Direzione medica 0039(0)382078501 direzionemedica@cnao.it

Locations
Layout table for location information
Italy
CNAO Recruiting
Pavia, Italy, 27100
Contact: Cristina Bono, MSc    +39(0)382078613    cristina.bono@cnao.it   
Sponsors and Collaborators
CNAO National Center of Oncological Hadrontherapy
Foundation IRCCS San Matteo Hospital
Investigators
Layout table for investigator information
Principal Investigator: Francesca Valvo, MD CNAO National Center of Oncological Hadrontherapy
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Francesca Valvo, Principal investigator, CNAO National Center of Oncological Hadrontherapy
ClinicalTrials.gov Identifier: NCT03822936    
Other Study ID Numbers: CNAO 35/2017 C
First Posted: January 30, 2019    Key Record Dates
Last Update Posted: September 5, 2021
Last Verified: August 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Francesca Valvo, CNAO National Center of Oncological Hadrontherapy:
carbon ion radiation therapy
exocrine pancreas
pancreas tumour
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Pancreatic Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Fluorouracil
 Oxaliplatin
Irinotecan
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors